Embecta Corporation (EMBC)

Embecta Corp.'s stock price has been impacted by several events in the past six months. The stock experienced a decline of 43.10% over the past year. Despite exceeding EPS expectations for Q4 2025, the company's revenue fell short of projections, leading to a negative stock price reaction. The company also announced a quarterly cash dividend of $0.15 per share on November 25, 2025, and changes to its Board of Directors around November 17, 2025. Insider trading activity includes a purchase of 13,000 shares by DAVID F MELCHER and a sale of 3,100 shares by MILTON MAYO MORRIS.

Specific detailed information on Embecta Corp.'s demand seasonality is not readily available without a specialized account, general market seasonality data for EMBC is displayed to identify seasonal patterns in monthly returns. The company's revenue is heavily reliant on the diabetes care market, which is influenced by demographic trends. The demand for insulin delivery devices is generally considered durable due to the increasing global demographic needing these devices. However, any technological breakthroughs in diabetes prevention or treatment could decrease demand for Embecta's products.

Embecta Corp. is a global medical device company focused on improving the health of individuals with diabetes. It operates in the Healthcare sector, specifically in the Medical Instruments & Supplies and Medical Equipment, Supplies & Distribution industries. Embecta's product portfolio includes insulin delivery devices and digital applications for diabetes management. The company distributes its products through wholesalers and distributors. Embecta was established as a spin-off from Becton, Dickinson and Company (BD) in April 2022 and is headquartered in Parsippany, New Jersey.

Embecta Corp. has a global geographic footprint, providing solutions to people living with diabetes in the United States and internationally. A majority of the company's revenue is derived from the United States. The company is also focused on expanding its presence in emerging markets where diabetes prevalence is rising. Embecta has been undergoing a global brand transition, with over 95% of its U.S. and Canadian revenue converted to the Embecta brand, and global transition activities expected to be largely complete in most regions by the end of 2026.

Embecta has undertaken initiatives that could positively impact its brand reputation. On World Diabetes Day, November 14, 2025, Embecta announced a major new commitment to Direct Relief. The company is also advancing a global brand transition, with significant progress in North America and global activities expected to be largely complete by the end of 2026. Embecta's focus on patient unmet needs and market expansion, along with its commitment to updating and developing enhanced technology for its product portfolio, contributes to its reputation as a company dedicated to diabetes care. However, the company operates in a highly competitive market and faces risks such as supply chain disruptions and competitive pressure, which could indirectly affect its reputation if not managed effectively.

Embecta Corp. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock. Approximately 59.58% to 84.85% of the company's stock is owned by institutional investors, 3.20% by insiders, and 11.95% to 25.28% by public companies and individual investors. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, American Century Companies Inc, iShares Core S&P Small-Cap ETF, River Road Asset Management, LLC, Deerfield Management Company, L.p. (series C), State Street Corp, Yacktman Asset Management Lp, and Jefferies Financial Group Inc.